Ted Frank, director at the Hamilton Lincoln Law Institute and the Center for Class Action Fairness, at the Federalist Society Annual Lawyers Convention at the Mayflower Hotel in Washington, on Thursday, November 14, 2019.
A class action settlement over the brain health supplement Neuriva was nearing final approval when objector Ted Frank stepped in, calling a proposed labeling change in the deal “nothing but worthless window dressing.”
Defendants Reckitt Benckiser LLC and RB Health (US) LLC fired back. This month, they brought a motion to strike Frank’s entire filing, as well as that of the organization Truth in Advertising Inc., which filed an amicus brief opposing the settlement. The motion alleges that Frank, who is serving as the objector in the case, rather than an objector’s lawyer, manufactured his standing as a class member by purchasing Neuriva once he knew about the settlement.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
